Commentary: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications

Annals of Clinical and Laboratory Science

Volumn 35, Issue 3, 2005, Pages 227-229

  Cao, Tong ^a   Heng, Boon Chin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Downregulation; Interference; Intrabody; Molecuar therapeutics; RNAi

Indexed keywords

CELL ANTIBODY; RECOMBINANT ANTIBODY; ANTIBODY; PROTEIN;

APOPTOSIS; CELLULAR DISTRIBUTION; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; TECHNOLOGY; ARTICLE; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIBODIES; PROTEINS; RNA INTERFERENCE;

EID: 23844524700     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Zamore PD, Tuschl T, Sharp PA, Barrel DP. RNAi: double-stranded RNA direcrs the ATP-dependenr cleavage of mRNA ar 21 ro 23 nucleoride inrervals. Cell 2000;101:25-33.
2. Hurvagner G, Zamore PD. A microRNA in a multiple Turnover. RNAi enzyme complex. Science 2002;297:2056-2060.
3. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
4. Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 2000;5:107-114.
5. Silva J, Chang K, Hannon GJ, Rivas FV. RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene. 2004;23:8401-8409.
6. Heidenreich O. Oncogene suppression by small interfering RNAs. Curr Pharm Biotechnol 2004;5:349-54
7. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res 2004;14:460-466.
8. Tuschl T, Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 1001;2:158-167.
9. Marasco WA. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy, Immunotechnology 1995;1:1-19.
10. Wheeler YY, Chen SY, Sane DC. Intrabody and intrakine strategies for molecular therapy, Mol Ther 2003;8:355-366.
11. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins, Science 1988;242:423-426.
12. Carlson JR. A new means of inducibly inactivating a cellular protein, Mol Cell Biol 1988;8:2638-2646.
13. Tanaka T, Rabbitts TH. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation, EMBO J 2003;22:1025-1035.
14. Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH, Schweighoffer F, Teillaud JL, Tocque B. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 1988;58:1170-1176.
15. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995;96:2980-2989.
16. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. PNAS USA 1993;90:7889-7893.
17. Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, Reitz MS, Gallo RC. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med 1995;1:667-673.
18. Duan L, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther 1995;6:1561-1573.
19. Sledz CA, Williams BR RNA interference and double-stranded-RNA-activated pathways, Biochem Soc Trans 2004;32:952-956.
20. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004;20:521-524.
21. Snove O, Holen T. Many commonly used siRNAs risk off-target activity, Biochem Biophys Res Commun 2004;319:256-263.
22. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004;10:12-18.
23. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-839.
24. Cattaneo A, Biocca S The selection of intracellular antibodies. Trends Biotechnol 1999;17:115-121.
25. Zhou P, Bogacki R, McReynolds L, Howley PM Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins, Mol Cell 2000;6:751-756.
26. Tse E, Rabbitts TH. Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy, PNAS USA 2000;97:12266-12271.
27. Hust M, Dubel S. Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol 2005;295:71-96.
28. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004;316:1050-1058.
29. Yuan B, Latek R, Hossbach M, Tuschl T, Lewitter F. siRNA Selection server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 2004;32(Web Server issue):W130-134.
30. Chalk AM, Wahlestedt C, Sonnhammer EL. Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun 2004;319:264-274.